BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Archives
  • July 2025
  • June 2025
  • May 2025
  • March 2025
  • February 2025
  • January 2025
  • December 2024
  • November 2024
  • September 2024
  • August 2024
  • July 2024
  • May 2024
  • April 2024
  • December 2023
  • October 2023
  • August 2023
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • December 2021
  • November 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
BioTech Health X
  • BioTech News
  • BioTech CEO Interviews
  • Contact Us
Subscribe

Browsing Tag

T Cell Receptors

2 posts

T-cell receptor (TCR) is a protein complex found on the surface of T cells, or T lymphocytes, that is responsible for recognizing fragments of antigen as peptides bound to major histocompatibility complex (MHC) molecules.

The human body’s own immune system has nearly limitless capacity to detect abnormalities. This ability is achieved by the related structures of two molecules, immunoglobulins and T cell receptors (TCR).

The TCR, a defining structure of T cells, is a transmembrane heterodimer consisting of either an alpha and beta chain or delta and gamma chain linked by a disulphide bond. Within these chains are complementary determining regions (CDRs) which determine the antigen to which the TCR will bind. TCRs activate the T cells in which they reside leading to a plethora of immune responses. Harnessing the power of this response and of TCR specificity is leading to a new generation of extremely promising immunotherapies.

Celyad-Oncology-Pauses-CYAD-101-002-Keynote-B79-Phase-1-Trial-After-2-Deaths-Reported

Biotech NewsCelyad Oncology Pauses CYAD-101-002 (Keynote-B79) Phase 1 Trial After 2 Deaths Reported

  • BioTech Health X
  • February 28, 2022
Clinical-stage biotechnology company Celyad Oncology (NASDAQ: CYAD) recently announced that the company has voluntarily paused the CYAD-101-002 (KEYNOTE-B79)…
0 Shares
0
0
0
0
0
0
0
Repertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery T Cell Receptors

Biotech NewsRepertoire Immune Medicines Enters Collaboration with Yale to Research Multiple Sclerosis Novel Antigen Discovery & T Cell Receptors

  • BioTech Health X
  • April 29, 2021
The collaboration between Repertoire and Yale seeks to identify novel antigenic reactivity of T cells in patients with…
0 Shares
0
0
0
0
0
0
0
Recent Posts
  • Vigil Neuroscience (VIGL): The Tiny Biotech Sanofi Just Bet $600M On
  • Agios (AGIO) Could Explode in 2025—And It’s Not Just Hype
  • Hinge Health (HNGE) IPO’d Big—But It’s Just Getting Started
  • Warren Buffett Missed This One: Why Johnson & Johnson (JNJ) May Be the Best Buy He Never Made
  • Buy the Dip? Molina Healthcare (MOH) Just Hit a 52-Week Low—and the Upside Is Stunning
Recent Comments
  • Novavax Announces Robust First Quarter 2024 Results and Strategic Partnerships • BioTech Health X on Novavax and Sanofi Forge $1.2 Billion Alliance to Boost COVID and Flu Vaccine Efforts
  • Thomas Shentz on Cellarity Expands Leadership Team to Continue Evolution of Breakthrough Platform to Encode Biology and Purposefully Create New Drugs
  • Tomasz Michałowski on Exclusive: Cel-Sci CEO Geert Kersten Talks Multikine, FDA Approval, CVM Future
  • Presenters Announced for 2021 William Blair Biotech Conference • BioTech Health X on William Blair Biotech Focus Conference 2021 Panel Schedule
Featured Posts
    • July 6, 2025
    Vigil Neuroscience (VIGL): The Tiny Biotech Sanofi Just Bet $600M On
    • July 6, 2025
    Agios (AGIO) Could Explode in 2025—And It’s Not Just Hype
    • July 6, 2025
    Hinge Health (HNGE) IPO’d Big—But It’s Just Getting Started
    • July 6, 2025
    Warren Buffett Missed This One: Why Johnson & Johnson (JNJ) May Be the Best Buy He Never Made
    • July 6, 2025
    Buy the Dip? Molina Healthcare (MOH) Just Hit a 52-Week Low—and the Upside Is Stunning
Recent Posts
  • Buy the Biotech Blue-Chip Before the Surge: Why Amgen (AMGN) Could Soar in 2025
    • July 6, 2025
  • Rigel Pharmaceuticals (RIGL) is Quietly Building a Biotech Empire
    • July 6, 2025
  • Wall Street’s Best-Kept Biotech Secret? Why Pharvaris (PHVS) Could Be the Next $3 Billion Breakout
    • July 4, 2025
Categories
  • BioTech CEO Interviews (9)
  • Biotech Info (1)
  • Biotech News (243)
  • Uncategorized (1)
Author
Hello, I’m
BioTech Health X
Follow
BioTech Health X
Designed & Developed by BioTech Health X
  • About BioTech Health X
  • List of Modern Life Science Technologies
  • Biotechnology Company Directory – List of Major Biotech Companies
  • Contact Us
  • Privacy Policy

Subscribe to
Our Updates

Back to top